COVID-19 cases occurred before the Huanan Market cluster began

Status CONTESTED, confidence 0.82 — high confidence that the claim is genuinely contested, not that it is true.

Evidence for pre-market cases: - Huang et al. (The Lancet, 24 Jan 2020) documented a patient with symptom onset 1 Dec 2019 and no market link; the report has never been formally corrected or retracted. This is well established at the level of documentation. - Molecular-clock/phylodynamic estimates independently place the most recent common ancestor / first human infection around mid-November 2019, consistent with infections circulating before the recognized market cluster.

Evidence against: - Worobey (Science 2021, "Dissecting the early COVID-19 cases in Wuhan") argues the 1 December onset attributed to the first reported patient (a 41-year-old accountant) is a transcription error; his true COVID onset was ~16 December, corroborated by a Wuhan clinicians' study, an interview, and hospital records, with a formal Science correction. Re-dating him leaves a market-linked vendor (~11 December) as the earliest documented case. - Worobey et al. (Science 2022) argue the earliest December cases — including those without a direct market link — were geographically centered on the market.

Why this resolves to CONTESTED rather than VERIFIED or CONTRADICTED: - The supporting anchor is verified only as to documentation, not accuracy. That Huang et al. reported a 1 December, no-market case is not in dispute; whether that date is correct is precisely what is contested. Documentation strength is not accuracy strength, so it cannot on its own establish that a real case preceded the market cluster. - The two contradicting lines are themselves contested, not verified. The accuracy crux (true onset 16 vs 1 December) rests on Worobey's transcription-error argument, which is credible and mainstream but has not corrected the Lancet record and is not universally accepted. The "vendor was earliest" ordering is challenged by ascertainment-bias critiques (e.g., Chan 2023; Weissman 2024; Stoyan & Chiu, JRSS 2024) arguing early surveillance was skewed toward market-linked cases; Worobey and Débarre published replies (2024) defending market centrality and arguing case definitions did not require a market link. This exchange remained live in the peer-reviewed statistical literature through 2024 with no resolution.

Because the supporting documentation cannot alone establish accuracy and the contradicting evidence is itself contested, the parent sits at CONTESTED. Credible peer-reviewed argument persists on both sides — the strongest signal toward CONTESTED. The single linked instance (an overview of the origins dispute) frames pre-market cases as an unresolved two-sided crux, consistent with this status.

Materiality of subclaims: the VERIFIED documentation subclaim (23dad9b3) anchors the FOR case only at documentation level; the accuracy crux (abf9ee9f, CONTESTED) and the "vendor earliest" claim (bb62598e, CONTESTED) are the load-bearing points against, both unresolved. No new load-bearing dependency was discovered; the FOR/AGAINST decomposition remains accurate. Confidence 0.82: the recent sharpening of the documentation-vs-accuracy distinction reinforces rather than alters the verdict.